Search by Drug Name or NDC
NDC 00169-2030-11 SOGROYA 6.7 mg/mL Details
SOGROYA 6.7 mg/mL
SOGROYA is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novo Nordisk. The primary component is SOMAPACITAN.
MedlinePlus Drug Summary
Somapacitan-beco injection is used to replace growth hormone (a natural hormone produced by your body) in adults with growth hormone deficiency. Somapacitan-beco injection is also used to replace growth hormone and to increase growth in children 2.5 years of age or older with growth hormone deficiency. Somapacitan-beco is a human growth hormone (hGH) analog. It works by replacing growth hormones that are normally produced in the body.
Related Packages: 00169-2030-11Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Somapacitan-beco Injection
Product Information
NDC | 00169-2030 |
---|---|
Product ID | 0169-2030_49f6746f-c935-45c4-af35-02df5db71e87 |
Associated GPIs | |
GCN Sequence Number | 081477 |
GCN Sequence Number Description | somapacitan-beco PEN INJCTR 10MG/1.5ML SUBCUT |
HIC3 | P1A |
HIC3 Description | GROWTH HORMONES |
GCN | 48603 |
HICL Sequence Number | 046831 |
HICL Sequence Number Description | SOMAPACITAN-BECO |
Brand/Generic | Brand |
Proprietary Name | SOGROYA |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | somapacitan-beco |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 6.7 |
Active Ingredient Units | mg/mL |
Substance Name | SOMAPACITAN |
Labeler Name | Novo Nordisk |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA761156 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00169-2030-11 (00169203011)
NDC Package Code | 0169-2030-11 |
---|---|
Billing NDC | 00169203011 |
Package | 1 SYRINGE, PLASTIC in 1 CARTON (0169-2030-11) / 1.5 mL in 1 SYRINGE, PLASTIC |
Marketing Start Date | 2023-05-01 |
NDC Exclude Flag | N |
Pricing Information | N/A |